MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1): A NOVEL MARKER FOR ARTERIOVENOUS FISTULA FAILURE.
Gamal A.Tawfik (MD), Fawzy A. Khalil (MD), Seham A. Omar (MD), Mohammed M. Keshawy (Msc) and Hamdy Sliem(MD)*
ABSTRACT
Background
Emerging evidences suggest that inflammation is involved in the pathogenesis of cardiovascular diseases.
Monocyte chemoattractant protein-1 (MCP-1) has a central role in atherogenesis. The study was performed as a
cross sectional study aiming at determining the role of MCP-1 in hemodialysis (HD) induced inflammation and
dyslipidemia in relation to arteriovenous fistula (AVF) failure among end stage renal disease (ESRD) patients.
Methods: 90 patients in Ismailia governorate, Egypt were enrolled in the study. Predialysis and postdialysis
MCP-1 gene expression, CRP and lipid profile were done in addition to standard laboratory work up for ESRD
patients. Results: The patients` mean age was 46.35 years, 63.33 % were males. Predialysis MCP-1 , postdialysis
MCP-1 and predialysis CRP levels are significantly higher in patients who had experienced arteriovenous fistula
(AVF) failure. Conclusion: MCP-1 can be used as a marker for dialysis induced inflammation and AVF failure.
Keywords: MCP-1, ESRD and AVF failure.
[Full Text Article]
[Download Certificate]